CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Myrbetriq Mirabegron Overactive bladder List with criteria/condition Complete
Myrbetriq Mirabegron Overactive bladder Withdrawn
N/A everolimus Renal angiomyolipoma associated with tuberous sclerosis complex Reimburse with clinical criteria and/or conditions Active
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Reimburse with clinical criteria and/or conditions Complete
N/A Pembrolizumab Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete
N/A Nivolumab and Ipilimumab Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete
N/A Nab-paclitaxel Solid tumours Reimburse with clinical criteria and/or conditions Complete
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Complete
N/A dapagliflozin Chronic kidney disease Reimburse with clinical criteria and/or conditions Complete
N/A abiraterone, prednisone, docetaxel Metastatic castration sensitive prostate cancer (mCSPC) Reimburse Complete
N/A rivaroxaban Venous thromboembolic events (VTE) Reimburse with clinical criteria and/or conditions Active
n/a abiraterone acetate and prednisolone High-risk non-metastatic prostate cancer Reimburse with clinical criteria and/or conditions Complete
N/A imiquimod Gynecological cancers Withdrawn
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
N/A mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
N/A Nab-paclitaxel Gastrointestinal cancer Active
N/A Enzalutamide Genito-urinary cancer (prostate cancer) Active
N/A nab-paclitaxel Gastrointestinal cancer Active
N/A dimethyl fumarate Multiple Sclerosis (MS) Active
N/A teriflunomide Multiple Sclerosis (MS) Active
N/A nivolumab ipilimumab Melanoma Active
N/A blinatumomab Acute lymphoblastic leukemia, pediatrics Active
N/A bevacizumab and lomustine Recurrent glioblastoma multiform Reimburse with clinical criteria and/or conditions Complete
N/A trametinib Gynecological cancers Active
Naglazyme Galsulfase (Drug Plan Submission) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) List with clinical criteria and/or conditions Complete
Last Updated : September 20, 2024